dr. Jos Elbers

Medicine and Dentistry

1. Neoplasm 100%
2. Head and Neck Squamous Cell Carcinoma 84%
3. Immunotherapy 56%
4. Radiation Therapy 42%
5. Immunosuppressive Treatment 42%
6. Non Small Cell Lung Cancer 42%
7. Nivolumab 42%
8. Hypopharynx 42%
9. Oropharynx 42%
10. Chemoradiotherapy 42%
11. Squamous Cell Carcinoma 42%
12. Sentinel Lymph Node Biopsy 42%
13. Neck 42%
14. Larynx 42%
15. Ipilimumab 42%
16. Diseases 42%
17. Arm 35%
18. Immune Checkpoint Blockade 31%
19. Primary Tumor 21%
20. Overall Survival 18%
21. Tumor Cell 10%
22. Single Drug Dose 10%
23. Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptide Like 10%
24. Hypoxia 10%
25. Immune-Related Adverse Events 10%
26. Biopsy Technique 10%
27. Polyethylene Terephthalate 10%
28. Immune Checkpoint Inhibitor 8%
29. Proton Therapy 8%
30. Phase I Trials 8%
31. Photon Therapy 8%
32. Radiation Biology 8%
33. Lymph Duct 8%
34. Hypofractionated Radiotherapy 8%
35. Quality of Life 8%
36. Radioimmunotherapy 8%
37. Radiation Treatment Planning 8%
38. Immune System 8%
39. Treatment Group 8%
40. Hoarseness 8%
41. Metastasis Potential 6%
42. Metastatic Carcinoma 6%
43. Patient Selection 6%
44. Patient Characteristics 6%
45. Cancer Pathobiology 6%
46. Targeted Therapy 6%
47. Oncogene 6%
48. Tumor Biology 6%
49. Distant Metastasis 6%
50. Prognostic Factor 6%